miR-21 promotes a mesenchymal phenotype during TGF-β-induced EMT.

Biomarkers were evaluated after TGF-β-induced EMT (left column) and compared to effects of transfection (right columns) with either miR-21 agonist in resting EMCs (“Pre-miR-21) or with miR-21 antagonist during TGF-β-induced EMT (“α-miR-21”). All biomarkers are presented relative to control treatments (medium (first column), pre-miR scramble (second column), anti-miR scramble (third column). Representative pictures used for assessment of cell motility (wound size) are in Figure S5. *P<0.05, **P<0.01 as tested by a two-tailed t-test.